LEO Pharma and Advancing Innovation in Dermatology (AID) have announced they both want to accelerate early stage research and development projects with the potential to impact the lives of people living with skin conditions. To achieve this they will each contribute $500,000 into the Advancing Innovation in Dermatology Accelerator Fund. The non-profit fund was recently created to provide both seed capital and in-kind intellectual property and advisory services. It will step in to financially support clinical breakthroughs at those early stages that are too risky for most investors, and before government funding and commercial investment start. It will focus on product development and on driving innovative technologies within the field of dermatology.
Michael Sierra, PhD, Vice President of LEO Science & Tech Hub said: “Our vision for this initiative is to build a sustainable investment model that will spur further innovation in the dermatology space. We are excited to fill what we see as a major void in the early development process and are committed to keeping the patient at the centre of all endeavours.”
“LEO Pharma and Advancing Innovation in Dermatology (AID) have announced they both want to accelerate early stage research and development projects to impact the lives of people living with skin conditions“
Christian Antoni, MD, PhD, Senior Vice President of Global Development at LEO Pharma said: “LEO Pharma is proud to be involved in progressing innovations in dermatology by working together with renowned thought leaders and entrepreneurs in order to truly impact society.”
William Ju, MD, FAAD, President and a Co-founding Trustee of Advancing Innovation in Dermatology, Inc. said “We are grateful for LEO Pharma’s generosity and partnership and are excited to build collaborations that will spark the translation of science and engineering innovations into products that meaningfully improve patient outcomes.”